{"summary": "the lysosome pathway and ubiquitin-proteasome system (UPS) are the major mechanisms through which proteins are degraded intracellularly. the lysosome pathway and lysosome system (UPS) are the major mechanisms through which proteins are degraded intracellularly. proteasome inhibitor bortezomib is currently the front-line therapy for the treatment of newly diagnosed multiple myeloma patients. bortezomib is a substrate of several cytochrome P450 isoenzymes, but only mildly inhibits CYP2C19 and CYP2C9. the effects of proteasome inhibition on their transport function have not been elucidated. cholecystokinin-8 (CCK-8), estradiol 17-D-glucuronide (E217G), IGEPAL (NP-40), Hanks' Balanced Salt Solution (HBSS), dexamethasone, dimethyl sulfoxide (DMSO), Triton X-100, Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), N-ethylmaleimide, MG132 was purchased from EMD Millipore (Billerica, MA, USA) [3H]CCK-8 (specific activity 96 Ci/mmol) and [3H]E217G (specific activity 41.4 Ci/mmol) were obtained from American Radiolabeled Chemicals (St. Louis, MO, USA) all other reagents were procured from VWR International (Radnor, PA, USA) cell culture The human embryonic kidney (HEK) 293 stable cell lines overexpressing OATP1B1 (HEK293-OATP1B1) and OATP1B3 (HEK293-FLAG-OATP1B3) were provided by Dr. Dietrich Keppler [26, 27] the HEK293 stable cell line overexpressing FLAG-tagged OATP1B3 (HEK293-FLAG-OATP1B3) was established by transfection of pCM cells were overlaid with MatrigelTM at a final concentration of 0.25 mg/ml in phenol red-free DMEM supplemented with 2 mM L-glutamine, 1% (v/v) MEM NEAA, 100 units/ml of penicillin-streptomycin solution, 0.1 M dexamethasone, and 1% (v/v) ITS+ premix. Donors age Gender Race BMI Smoking Alcohol use Ex whole cell lysates were prepared using lysis buffer containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Na-deoxycholate, and CompleteTM protease inhibitor cocktail. whole cell lysates were not boiled, unless stated otherwise. eluted immunocomplexes were resolved through sodium dodecylsulfate\u201310% polyacrylamide gel electrophoresis (SDS-PAGE) after transferring the protein to the membrane, the blot was blocked with 5% milk in Tris-buffered saline with 0.05% Tween (TBST) images were captured using a bio-Rad ChemiDoc XRS imaging system (Bio-Rad Laboratories, cells were seeded at a density of 1\u20131.2 x 105 cells/well in 24-well culture plates. HEK293 stable cell lines or human SCH were either pre-incubated with culture medium containing testing compounds or vehicle control (pre-incubation) substrate concentrations used in the current studies were all below the reported Km values. hek293-OATP1B3 cells were pre-incubated with vehicle control or bortezomib (50 nM, 2 h) at the end of pre-incubation, the culture medium was aspirated. cells were rinsed with HBSS three times before lysing with Triton-X 100 (0.5% v/v) in DPBS. v = V m a x * S K m + S Surface biotinylation assay Experiments were conducted similarly to those published previously. hek293-OATP1B3 cells were seeded on 24-well plates at a density of 1.2 x 105 cells per well, cultured for 48 h, and then treated with bortezomib (50 nM) the supernatant was resolved on 10% SDS-PAGE (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and was then resolved on 10% SDS-PAGE (Bio-Rad Laboratories, Inc., Hercules, CA, USA) the blots were also probed with a GAPDH antibody (1:1000 dilution, Santa Cruz, Dallas, TX, USA) p-values were adjusted based on the Bonferroni\u2019s method. a random effect (experiment date or hepatocyte donor) allowed for treatment time/group-specific variation. complete protease inhibitor cocktail tablets were purchased from Roche Diagnostics (Indianapolis, IN, USA) MG132 was purchased from EMD Millipore (Billerica, MA, USA) [3H]CCK-8 and [3H]E217G were obtained from Perkin Elmer Life Science (Waltham, MA, USA) cells were washed once with PBS buffer and were subjected to immunoprecipitation and immunoblot. the human embryonic kidney (HEK) 293 stable cell lines overexpressing OATP1B1 (HEK293-OATP1B1) and OATP1B3 (HEK293-OATP1B3) were provided by Dr. Dietrich Keppler [26, 27] 5% (v/v) FBS, 1% (v/v) MEM NEAA, 2 mM L-glutamine, penicillin-streptomycin (10 U/ml), 1 M dexamethasone, and 4 g/ml insulin. cells were overlaid with MatrigelTM at a final concentration of 0.25 mg/ml in phenol red-free DMEM supplement. whole cell lysates were prepared by lysing cells with lysis buffer. whole cell lysates were first precleared by incubation with normal mouse IgG. whole cell lysates and eluted immunocomplexes were resolved through sodium dodecylsulfate\u201310% polyacrylamide gel electrophoresis (SDS-PAGE) after transferring the protein to the membrane, the blot was blocked with 5% milk in Tris-buffered saline with 0.05% Tween (TBST) the blots were incubated with the appropriate horseradish peroxidase-conjugate transport studies HEK293-OATP1B1 and -OATP1B3 cells were seeded at a density of 1\u20131.2 x 105 cells/well in 24-well culture plates. hek293 stable cell lines or human SCH were either pre-incubated with culture medium containing testing compounds or vehicle control (pre-incubation) hek293-OATP1B3 cells were pre-incubated with vehicle control or bortezomib (50 nM, 2 h) at the end of pre-incubation, the culture medium was aspirated. the cells were rinsed with ice-cold HBSS three times before lysing with DPBS. hek293-OATP1B3 cells were seeded on 24-well plates at a density of 1.2 x 105 cells per well, cultured for 48 h, and then treated with bortezomib (50 nM, 7 h) or vehicle control. the cells were then lysed with lysis buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl2, 1 mM EDTA, 0.1% S the beads were incubated with 2X Laemmli buffer for 1 h at room temperature. the supernatant was resolved on 10% SDS-PAGE. the blots were also probed with a GAPDH antibody. p-values were adjusted based on the Bonferroni method. a two-sided p-value of 0.05 defines statistical significance. results Ubiquitination of OATP1B1 and OATP1B3 with HA-tagged ubiquitin (HA-Ub) was performed in HEK293 cells. pCMV6-FLAG-OATP1B1 (A) or pCMV6-FLAG-OATP1B3 (B) vectors were transfected into HEK293 cells. same membrane was stripped and re-probed with FLAG or HA antibody. expression of HA-Ub, FLAG-OATP1B1 and FLAG-OATP1B3 confirmed in whole cell lysates. the effects of bortezomib treatment on the levels of ubiquitin-conjugated OATP1B1 and OATP1B3. bortezomib treatment has not been validated for immunoprecipitation. the HEK293-FLAG-OATP1B1 and -1B3 stable cells were used for this purpose. more ubiquitin-conjugated FLAG-OATP1B1 and FLAG-OATP1B3 proteins were detected in bortezomib-treated HEK293-FLAG-OATP1B1 and HEK293-FLAG-OATP1B3 cells. bortezomib treatment (50 and 250 nM, 2 and 7 h) did not affect protein levels of OATP1B1 and OATP1B3, HEK293-FLAG-OATP1B1 and\u2013FLAG-OATP1B3 stable cell lines were seeded at a density of 3x106 cells per 100-mm2 dish. cells were treated with bortezomib (Btz) (50 nM, 7 h) or vehicle control (CTL) ubiquitin-conjugated proteins were markedly increased after bortezomib treatment (50 nM, 7 h) in human SCH. no higher molecular weight bands of OAPT1B1 or OATP1B3 appeared in human SCH whole cell lysates. primary human hepatocytes [10, 40, 41], human basolateral membrane [27] and human liver tissues [40]. 98 kD molecular weight band of OATP1B1 in human SCH is at similar size as in the transporter-expressing stable cell line (Fig 2A middle panel). -actin served as the loading control. the effects of chloroquine treatment on total protein levels of OATP1B3 were determined in the HEK293-OATP1B3 stable cell line and in human SCH. the effects of chloroquine treatment on total protein levels of OATP1B3 were determined in the HEK293-OATP1B3 stable cell line. -treated cells vs. vehicle control treatment (CTL) were expressed as mean SD (n = 3) bortezomib (10\u2013250 nM) did not affect OATP1B3-mediated [3H]CCK-8 accumulation (1 M, 3 min) without bortezomib pretreatment. in human SCH pretreated with bortezomib at 50 and 250 nM for 7 h, accumulation of [3H]CCK-8 (1 M, 3 min) was significantly decreased to 0.64 0.05 and 0.62 0.07 fold of control. after pretreatment, cells were washed three times with HBSS buffer. cells were washed three times with the HBSS buffer. the [3H]CCK-8 accumulation was determined in the absence of bortezomib. in D and E, HEK293-OATP1B3 and HEK293-Mock cells were pretreated. a generalized linear mixed model was fit to the data in A-F. p-values were adjusted based on the Bonferroni method. the OATP1B3-mediated uptake of [3H]pitavastatin was linear. bortezomib pretreatment (50 nM, 7 h) significantly decreased the maximum transport velocity (Vmax) values of CCK-8 transport compared with vehicle control treatment (92.25 14.2 vs. 133.95 15.5 pmol/mg protein/min, p 0.05), without affecting the Km values. concentration-dependent accumulation of CCK-8 was determined in HEK293-OATP1B3 cells pretreated with control (CTL) or bortezomib (Btz) (50 nM, 7 h) solid and dashed lines represent the best fit lines of the Michaelis\u2013Menten equation to the data of vehicle control (CTL) and bortezomib (Btz) pretreatment. the total protein levels of OATP1B3 in bortezomib-treated cells were 0.82 0.2 fold of control. the surface protein fraction was not contaminated with intracellular protein. effects of bortezomib on [3H]pitavastatin and [3H]E217G transport in HEK293-OATP1B1 cells. in human SCH, co-incubation with positive control bromosulfophthalein (BSP) decreased [3H]pitavastatin accumulation to 0.27 0.01 fold of control. pretreatment with bortezomib (50 nM) did not significantly affect [3H]pitavastatin accumulation (1 M, 0.5 min) following pretreatment, cells were washed three times with HBSS buffer. the [3H]pitavastatin accumulation was determined in the absence of bortezomib. model-estimated fold change and associated SE in [3H]E217G accumulation. effects of pretreatment with other proteasome inhibitors, MG132, epoxomicin and carfilzomib, on OATP1B1- and 1B3-mediated transport. pretreatment with MG132 (10 M), epoxomicin (50 nM) and carfilzomib (200 nM) for 2 h significantly decreased [3H]CCK-8 accumulation to 0.71 0.01, 0.81 0.04, and 0. HEK293-OATP1B3 cells were seeded at a density of 1.2 x 105 cells/well in 24-well plates. model-estimated fold change and associated SE in [3H]CCK-8 accumulation (1 M, 3 min) in HEK293-OATP1B3 cells. co-immunoprecipitation of FLAG-tagged OATP1B1 and OATP1B3 with HA-tagged ubiquitin (HA-Ub) was performed in HEK293 cells that were transiently transfected with vectors expressing FLAG-OATP1B1 or FLAG-OATP1B3. HA-Ub was readily detected only when HA-Ub was co-expressed with FLAG-OATP1B1 or FL whole cell lysates were subjected to immunoprecipitation (IP) with HA or FLAG antibody. the same blot was stripped and re-probed with HA or HA antibody. expression of HA-Ub, FLAG-OATP1B1 and FLAG-OATP1B3 confirmed in whole cell lysates. HEK293-FLAG-OATP1B1 and -1B3 proteins can be readily immunoprecipitated using a FLAG antibody. bortezomib-treated HEK293-FLAG-OATP1B1 and -1B3 proteins can be readily immunoprecipitated. the total protein levels of FLAG-OATP1B1 and FLAG-OATP1B3 in bortezomib-treated cells were 1.1 0.03 and 0.97 0.03 fold of vehicle control treatment. treatment with bortezomib (50 and 250 nM, 2 and 7 h) also efficiently inhibited proteasome activity in HEK293-OATP1B1 and HEK293-OATP1B3 cells. whole cell lysates (50 g) of HEK293-FLAG-OATP1B1 (A) and HEK293-FLAG-OATP1B3 (B) cells treated with bortezomib (50 nM, 7 h) or vehicle control were subjected to immunoprecipitation (IP) with FLAG antibody. -actin served as loading control. the total ubiquitin-conjugated proteins were markedly increased after bortezomib treatment (50 nM, 7 h) in human SCH. no higher molecular weight bands of OAPT1B1 or OATP1B3 appeared in human SCH whole cell lysates following bortezomib treatment. immunoblot of ubiquitin in whole cell lysates of human SCH treated with bortezomib (Btz) (50 and 250 nM) or vehicle control. -actin served as loading control. ATP1B3 protein levels to 1.85 0.3 (mean SD, n = 3; Fig 4A) and 1.49 0.16 (mean SD, n = 3 donors; Fig 4B) fold of vehicle control in HEK293-OATP1B3 cells and human SCH. bortezomib on OATP1B3-mediated transport in HEK293-OATP1B3 cells and in human SCH. the effects of bortezomib on OATP1B3-mediated transport in HEK293-OATP1B3 cells were determined using all three substrates, [3H]CCK-8, [3H]E217G and [3H]pitavastatin. bortezomib (10\u2013250 nM) did not affect [3H]CCK-8 accumulation (1 M, 3 min) model-estimated fold change and associated SE of [3H]CCK-8 accumulation (1 M, 3 min) in HEK293-OATP1B3 cells without any pre-incubation (Co-incubation) after pretreatment, cells were washed three times with the HBSS buffer, and the [3H]CCK-8 accumulation was determined in the absence of bortezomib. bortezomib cells were pretreated with vehicle control (CTL) or bortezomib at the indicated concentrations and time (Pre-incubation) in D and E, HEK293-OATP1B3 and HEK293-Mock cells were pretreated with vehicle control (CTL) or bortezomib. 1B3-mediated uptake of [3H]pitavastatin (1 M) was linear, at least up to 90 sec. bortezomib pretreatment significantly decreased [3H]CCK-8 accumulation to 0.71 0.02 fold of vehicle control pretreatment. effects of bortezomib treatment on the transport kinetics of CCK-8 and surface protein levels of OATP1B3 in HEK293-OATP1B3 cells. bortezomib pretreatment (50 nM, 7 h) significantly decreased the maximum transport velocity (Vmax) values of CCK-8 transport compared with vehicle control treatment (92.25 14.2 vs. 133.95 15.5 pmol/mg protein/min the student\u2019s t-test was conducted to compare the Vmax and Km values between bortezomib and vehicle control pretreatment. surface levels of OATP1B3 were determined via biotinylation, followed by immunoblotting with OATP1B3 and Na-K-ATPase antibodies. effects of bortezomib on OATP1B1-mediated [3H]pitavastatin and [3H]E217G transport in HEK293-OATP1B1 cells. pretreatment with bortezomib (50 and 250 nM, 2 and 7 h) did not significantly affect the accumulation of [3H]pitavastatin (1 M, 0.5 min) HEK293-OATP1B1 cells were seeded at a density of 1.2 x 105 cells/well in a 24-well plate and were cultured to confluence. model-estimated fold change and associated SE in [3H]pitavastatin accumulation (1 M, 0.5 min) in HEK293-OATP1B1 cells pretreated with bortezomib (Btz) vs. vehicle control (CTL) at model-estimated fold change and associated SE in [3H]pitavastatin accumulation (1 M, 0.5 min) in human SCH pre-incubated with bortezomib (50 nM for 7 h) or co-incubated with positive control bromosulfophthalein (BSP) (100 M) vs. vehicle CTL in HEK293-OATP1B1 cells. carfilzomib is a second-generation proteasome inhibitor drug with an unbound Cmax of 176 nM. pretreatment with MG132 (10 M), epoxomicin (50 nM) or carfilzomib (200 nM) for 2 h significantly decreased [3H]CCK-8 accumulation to 0.71 0.01, 0.81 0.04, and 0.79 0.02 fold of control. model-estimated fold change and associated SE in HEK293-OATP1B3 cells. fold changes were estimated by linear mixed effects models. p-values were adjusted based on the Bonferroni method. the ubiquitination of OATP1B1 and OATP1B3 is determined by proteasome inhibitors. the HA-Ub-conjugated FLAG-tagged OATP1B1 and OATP1B3 proteins were only observed in cells in which HA-Ub was co-expressed with FLAG-OATP1B1/OATP1B3. these molecular weights are comparable to previously published molecular weights of OATP1B1 and OATP higher molecular weight bands (250 kD) of FLAG-OATP1B1 and FLAG-OATP1B3 were observed in FLAG immunoblotting after FLAG immunoprecipitation in cells transiently expressing FLAG-OATP1B1 and/or FLAG\u2013OATP1B3. a similar phenomenon was observed for FLAG-OATP1B1 and FLAG-OATP1B3. treatment with tunicamycin, an inhibitor of protein N-linked glycosylation, markedly reduced the amount of high molecular weight band of OATP1B1 and OATP1B3 observed in current studies. the ubiquitin proteasome system is not only involved in the degradation of cytosolic proteins, but also in the degradation of some plasma membrane proteins. bortezomib treatment did not affect total protein levels of OATP1B1 and OATP1B3 in human SCH or in HEK293 stable cell lines expressing untagged OATP1B1 and OATP1B3. ubiquitin-proteasome system may play a less important role in the degradation of OATP1B1 and OATP1B3 under the current conditions. ubiquitination of endogenous OATP1B1 and OATP1B3 warrant further characterization in primary human hepatocytes using validated OATP1B1 and OATP1B3 antibodies. proteasome inhibition decreases serotonin transporter (SERT)-mediated serotonin uptake [16] and the efflux function of P-gp [17]. in and carfilzomib significantly decreased OATP1B3-mediated CCK-8 transport. bortezomib pretreatment appears to be specific to OATP1B3-mediated CCK-8 transport. bortezomib pretreatment does not affect pitavastatin accumulation in human SCH. bortezomib pretreatment markedly decreased the Vmax values of OATP1B3-mediated CCK-8 transport without apparently affecting the Km values of CCK-8 transport. bortezomib pretreatment (50 nM, 7 h) markedly decreased the Vmax values of OATP1B3-mediated transport without apparently affecting the Km values of CCK-8 transport. immunoblot in HEK293-FLAG-OATP1B3 cells with OATP1B3 (A) and FLAG (B) antibody. -actin served as the loading control. total protein levels in bortezomib-treated cells vs. CTL were expressed as mean SD (n = 3) representative immunoblot images are shown from at least 3 independent experiments. blot was first probed with an OATP1B1 antibody (left panel) time-dependent accumulation of [3H]pitavastatin was determined in HEK293-OATP1B3 and HEK293-Mock cells. data represent mean SD (n = 1 in triplicate) p-values were adjusted based on the Bonferroni method. an LDH assay was performed to measure the cytotoxicity in HEK293 stable cell lines expressing OATP1B1, OATP1B3, FLAG-OATP1B1 or FLAG-OATP1B3."}